Usage: QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a superoxide dismutase 1 (SOD1) gene mutation. Approval is based on reduced plasma neurofilament light chain (NfL) levels, with continued approval pending verification of clinical benefit from further trials.